Valeo Pharma (VPHIF) Stock Statistics & Valuation Metrics

Valeo Pharma has a market cap or net worth of $3.24M. The enterprise value is $69.30M.

Valeo Pharma has 98,675,430 shares outstanding. The number of shares has decreased by -2.65% in one year.

Valeo Pharma’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is -67.29%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Valeo Pharma had revenue of 53.91M and earned -27.81M in profits. Earnings per share was -0.32.

In the last 12 months, operating cash flow was -4.28M and capital expenditures -5.12M, giving a free cash flow of -9.40M billion.

Valeo Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Valeo Pharma upcoming earnings date is Sep 10, 2025, TBA (Confirmed).

Valeo Pharma as a current ratio of 1.25, with Debt / Equity ratio of -111.18%

In the past 12 months, Valeo Pharma has paid 0.00 in taxes.

Valeo Pharma EV to EBITDA ratio is -6.16, with an EV/FCF ratio of -3.30.

Valeo Pharma has $7.13M in cash and marketable securities with C$70.08M in debt, giving a net cash position of $62.96M billion.

Gross margin is 20.57%, with operating margin of -31.96%, and net profit margin of -51.58%.

The average price target for Valeo Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―